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INTRODUCTION 
 
Though Parkinson’s disease (PD) is a single diagnosis, 
it presents as a heterogeneous disorder with some 
patients experiencing a more akinetic phenotype with 
prevailing rigidity where others may be less affected by 
rigidity but have a more tremor dominant disease [1]. 
The measurement of these different forms is now 
possible using MRI and reveals that certain neural 
loops, for example a ‘cerebello-thalamo-cortical loop’ 
can be associated with specific symptomology [2, 3]. 
There is mounting evidence to justify extending the 
study of PD from the basal ganglia to include 
connecting pathways to the cerebellum [4, 5]. However, 
moving our attention to the cerebellum where there is  
 
no overt cell loss warrants a careful understanding of 
what is happening in this region of the brain at a 
molecular and cellular level; this fits with recent 
proposals that the cerebellum is due for greater attention 
in the field of PD [5–7].  
 
Mitochondrial dysfunction is a key feature of ageing 
and neurodegenerative disease [8, 9]. The link between 
mitochondrial dysfunction and disease is particularly 
well described in PD where it has been linked to both 
familial and sporadic forms. Mitochondria in PD have 
been shown to undergo bioenergetic changes, DNA 
mutations, misregulation of fission and fusion and 
dynamics more generally; mutations in mitochondrial 
proteins Parkin and PINK1 are implicated in PD [10]. A 
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ABSTRACT 
 
Response to inflammation is a key determinant in many diseases and their outcomes. Diseases that commonly 
affect older people are frequently associated with altered inflammatory processes. Neuroinflammation has 
been described in Parkinson's disease (PD) brain. PD is characterized by the loss of dopaminergic neurons in the 
substantia nigra pars compacta and at the sub-cellular level, mitochondrial dysfunction is a key feature. 
However, there is evidence that a different region of the brain, the cerebellum, is involved in the 
pathophysiology of PD. We report relative levels of 40 pro- and anti-inflammatory cytokines measured in PD 
and control cerebellar mitochondria. These data were obtained by screening cytokine antibody arrays. In 
parallel, we present concentrations of 29 oxylipins and 4 endocannabinoids measured in mitochondrial 
fractions isolated from post-mortem PD cerebellum with age and sex matched controls. Our oxylipin and 
endocannabinoid data were acquired via quantitation by LC-ESI--MS/MS. The separate sample sets both show 
there are clearly different inflammatory profiles between the sexes in control samples. Sex specific profiles 
were not maintained in cerebellar mitochondria isolated from PD brains. 
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direct link between parkin and PINK1 and the STING 
inflammatory pathway connects pathways central to 
mitochondrial dynamics and neuroinflammation  
[11, 12]. The alpha-synuclein protein is regarded as 
central to PD pathology and has been implicated in 
neuroimmune response while also being involved in 
mitochondrial dysfunction. Mitochondrial associated 
membranes (MAMs) and mitochondrial damage-
associated molecular patterns (mtDAMPs) also directly 
connect mitochondria in processes leading to changes in 
inflammatory response [13, 14]. 
 
In PD it is accepted that more males than females have 
the disease, with some studies calculating a nearly 2:1 
ratio between sexes [15]. It is certainly possible that 
oestrogen may offer neuroprotection in females but 
direct evidence for this in PD is not yet forthcoming 
[16]. However, not only are females less likely to be 
diagnosed with Parkinson’s disease but sex differences 
are apparent in aspects of symptomology associated 
with this disease, for example swallowing disturbances, 
and dementia are associated more with male patients. 
Furthermore, normal human basal ganglia are sexually 
dimorphic, which might influence the onset and 
progression of PD [15]. When treating PD, it is apparent 
that there are sex differences in bioavailability of 
levodopa (the most potent medication for PD) even in 
much older post-menopausal patients. Females retain a 
higher availability for the drug than males with matched 
disease duration [17]. Sex differences in disease 
susceptibility and phenotype are evident in the clinic, 
but the molecular explanations for these are not 
established.  
 
Lipid profiling by mass spectrometry allows the 
absolute quantitation of biologically active molecules 
in complex tissue preparations [18]. Oxylipins are a 
group of metabolites produced via oxidation of 
polyunsaturated fatty acids (PUFAs) [19], they have 
been linked to pathways of inflammation, pain and 
ageing [20–22]. In PD mis-folding of the protein 
alpha-synuclein is associated with dopaminergic cell 
death in the substantia nigra. Studies of the interaction 
of alpha-synuclein with PUFAs has indicated a 
protective role for alpha-synuclein in the inhibition of 
harmful oxidation reactions which affect the PUFAs 
[23, 24].  
 
Arachidonic acid (AA) signalling is upregulated in the 
caudate-putamen and frontal cortex of unilaterally 6-
hydroxydopamine (6-OHDA) lesioned rats, a model for 
asymmetrical PD [25]. Arachidonic acid and its 
derivatives are modulated in inflammation and 
oxidative stress and these are factors associated with 
induction of neurodegeneration in age-related 
neurological disorders [26]. Signs of inflammation are 
found in many neurodegenerative diseases and can be 
attributed to interactions between glial and neuronal 
cells, activated by microglia and astrocytes [27, 28]. 
Pro-inflammatory cytokine contributions to the 
inflammasome associated with PD could be potential 
targets for therapy [29, 30]. However, the role of 
inflammation and the specific molecular signatures 
found in healthy ageing versus neurodegeneration must 
be delineated and understood throughout the brain, 
before therapies to regulate cytokine production can be 
promoted [31, 32]. 
 
Our study looked at molecular markers of inflammation 
measured in mitochondrial fractions derived from 
cerebellum to reveal whether there is a disease related 
process that connects with PD in this part of the human 
brain.  
 
RESULTS 
 
Variability in cytokine and oxylipin levels 
characterize the female control group  
 
Highly variable inflammatory cytokine expression 
was measured across female control cerebellar 
mitochondria when compared with the equivalent 
male control group (Figure 1A). Of the forty 
cytokines interrogated on the slide arrays, twenty-one 
inflammatory cytokines had different variance (f -test) 
between female and male controls, only one of these 
(IL-1β) had a greater variance in males. Both pro- and 
anti-inflammatory molecules were largely found to 
show greatest variance in female control groups (for 
comprehensive graphs see Supplementary Figure 2 
and datasets Table 6). Several very highly significant 
differences in pro-inflammatory molecules were 
found including IL-12p40, MIG and TNFRI (for 
abbreviations of molecules measured throughout see 
Supplementary Table 2). Very highly significant 
differences in variation were also found in anti-
inflammatory cytokines including IL-10 and IL-
12p70. Measurements of mean levels identified pro-
inflammatory cytokines RANTES (p=0.007) and GM-
CSF (p=0.0418) as significantly higher in female 
controls when compared with age-matched male 
control cerebellar mitochondria (Figure 1C). 
 
Significant differences in variance between female 
and male control oxylipin concentrations were found 
in AA, LA and pro-inflammatory 5-HETE, 9-
oxoODE, 9-HODE, 8-HETE, 8,9-EET, and also anti-
inflammatory 13oxoODE and 13-HODE (Figure 1B – 
and for comprehensive graphs see Supplementary 
Figure 1 and datasets Table 4). Again, the female 
control group showed the greater levels of variance in 
each case. 
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Fewer sex differences are found in cytokines and 
oxylipins of PD Braak 5-6 cerebellar mitochondrial 
fractions 
 
Comparison of cerebellar mitochondria isolated from 
severely affected brain tissues shows fewer differences 
between the sexes. However, some molecules still present 
with different variation in levels. Cytokines measured with 
different variance between the sexes were pro-
inflammatory MIP1α, MIP1β and TNFα which all showed 
a higher variance across the female Braak 5-6 group 
(Figure 1D and see Supplementary Table 6 for f-test data). 
Anti-inflammatory cytokines IL-4 and IL-12p70 showed a 
similar pattern of higher variance in female samples. For 
MCSF and TIMP-1 the male group has a greater degree of 
variation in cytokine levels than that found in females. 
 
Of the oxylipins measured, just two show a difference 
in variation between the sexes in PD Braak 5-6 groups, 
both have a greater variation across the male group PD 
Braak 5-6 (Figure 1E). 12-HPETE an anti-inflammatory 
oxylipin, is found to have a higher variation across the 
male PD Braak 5-6 group, this is also the case for the 
only other oxylipin to show a difference, 5,6-EET (see 
Supplementary Table 4 for f-test data). 
 
Endocannabinoid levels show greater variance in the 
control female group 
 
Though there are multiple reviews and studies on the 
effect of endo/cannabinoids on brains of mammalian 
models of PD [33, 34], the measurement of 
endocannabinoid species in human post-mortem PD 
brain has not been reported. Reflecting the datasets 
gathered from the oxylipin and cytokine measurements, 
we found that there was no mean difference between the 
four groups in the endocannabinoid species that were 
analysed (Figure 1F and Supplementary Table 7). 
However, once again the f-test showed there was a 
significant difference in variation when comparing the 
female group data with the PD Braak 5-6 female group 
in 3 of the four endocannabinoid species, namely 2-AG, 
AEA and PEA.  
 
The female PD group is characterized by a reduction 
in inflammatory markers 
 
Comparison of cerebellar mitochondrial oxylipin levels 
in female PD Braak 5-6 fractions with controls shows a 
significant reduction in the levels of thirteen oxylipins 
(Figure 2A). AA and pro-inflammatory molecules12-
HETE, TXB2, 5-HETE, 5-HPETE, 12-HPETE, 9-
HODE and 9-oxoHODE are all significantly reduced in 
the PD females. Also, five oxylipins with anti-
inflammatory roles were significantly reduced in the PD 
female samples these were 5,6-EET, 16-HETE, 17-
HDoHE, 13-HODE and 13-oxoODE (see 
Supplementary Table 3 for p values). 
 
Two cytokines, one pro-inflammatory ICAM-1 
(p=0.0274) and the other anti-inflammatory TIMP-2 
(p=0.036) were found to be significantly reduced in PD 
females when compared with controls (Figure 2B and 
Supplementary Table 5). 
 
Variation in levels of oxylipins in the female control 
group is attenuated in PD cerebellar mitochondria 
 
Comparison of oxylipin levels in control and PD Braak 
5-6 groups showed that the variation of oxylipin levels 
that characterize the female control cerebellar 
mitochondria is much reduced in the PD Braak 5-6 
group. Eleven oxylipins showed a significant reduction 
in variation (f-test) in the PD group, these were LA and 
PGE2; pro-inflammatory molecules 5-HETE, 5-
HPETE, 12-HPETE, 9-oxoODE, 9-HODE, 5,6-EET 
and17-HDoHE; anti-inflammatory oxylipins 13-
oxoODE and 13-HODE (Figure 2C also Supplementary 
Figure 1 and Table 4). 
 
Free fatty acids and PTGS2 levels are significantly 
altered in male PD Braak 5-6 cerebellar 
mitochondrial fractions 
 
We measured total free fatty acid levels in the cerebellar 
mitochondria from control, PD Braak 3-4 (more 
moderate pathology) and PD Braak 5-6 brains. Though 
the numbers of samples were limited there was an 
upward trend in the PD Braak 3-4 samples, becoming a 
significant increase in free fatty acid content (p=0.0164) 
in the more severely affected PD Braak 5-6 derived 
samples (Figure 3A). The enzyme prostaglandin synthase 
2 (PTGS2, also known as cyclooxygenase 2 or COX2) 
has a role in regulating inflammatory processes and is 
found to be increased in dopaminergic neurons of the 
substantia nigra in PD [35]. PTGS2 had not been 
previously measured in the cerebellar mitochondria of 
PD brains. In cerebellum samples we saw no change in 
PTGS2 levels in PD Braak 3-4 samples, however a 
significant drop in the levels of this enzyme in PD Braak 
5-6 samples (p=0.0307) was measured (Figure 3B). 
 
A pattern of higher levels of oxylipins is seen in 
PDBraak 3-4 males 
 
Many of the oxylipin species measured had a pattern of 
increased levels in Braak 3-4 male cerebellar 
mitochondria when compared with controls and Braak 
5-6 samples (figure 3C). A selection of the species that 
exhibited this pattern are shown, including LTB4 where 
significance is reached between samples from PD Braak 
3-4 and PD Braak 5-6 (p=0.0139). 
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Figure 1. Sex differences in inflammatory profiles of cerebellar mitochondria. (A) Cerebellar mitochondria of female controls have 
highly variable inflammatory cytokine expression compared with male controls. Twenty-one inflammatory cytokines showed significantly 
different variance between female and male controls. Twenty of these were significantly more variant in females. Control male n=9; control 
female n=8. (B) Oxylipin variance is significantly greater in cerebellar mitochondria of female controls than male controls. Female controls 
have significantly greater variance in nine oxylipins. Male control cerebellar mitochondrial oxylipin levels are less variant within the group. 
Control male n=5; control female n=5. (C) Two inflammatory cytokines are significantly increased in female compared to male controls. 
RANTES and GM-CSF were significantly increased in mean levels in female controls compared to male controls. Control male n=9; control 
female n=8. (D) Cerebellar mitochondria from PD Braak 5-6 females have greater variability in inflammatory cytokine expression than the 
Braak 5-6 males. Six of seven significant inflammatory cytokines showed higher variance in the PD Braak 5-6 female group than PD Braak 5-6 
males. PD Braak 5-6 male n=10; PD Braak 5-6 female n=9. (E) PD Braak 5-6 males and females show little variance in all but two cerebellar 
mitochondrial oxylipin levels. Two oxylipins have significantly higher variance values in PD Braak 5-6 males than females. PD Braak 5-6 male 
n=5; PD Braak 5-6 female n=5. All samples were age matched. A, B, D and E present inflammatory cytokine and oxylipins with significantly 
different variances (f-test). Refer to Supplementary Tables 4 and 6 for f values of oxylipins and inflammatory cytokines, respectively. Box plots 
display interleaved high and low. The horizontal line represents the mean. C shows significantly altered cytokines. Red title font represents 
pro-inflammatory cytokine. Displayed are mean levels ± SEM. (Mann-Whitney U-test). Refer to Supplementary Table 5 for p values. (F) 
Endocannabinoid variance is reduced in PD Braak 5-6 females. Female control group has heterogenous quantities of 2-AG, AEA and PEA 
compared with PD Braak 5-6 female group. Males do not show significant variation in endocannabinoid levels. Statistical analyses were 
carried out using GraphPad Prism (f-test). No significant differences were seen between the means of the groups (Kruskal-Wallis test with 
multiple comparison’s). Braak 5-6 male n=8; Braak 5-6 female n=9; control male n=8; control female n=6. All samples were age matched. 
Plots display mean ±SEM. Bars above plots represent statistically significant differences. Refer to Supplementary Table 7 for p and f values. 
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Figure 2. Molecular profiling of inflammation in female PD cerebellar mitochondria. (A) Oxylipin levels are lower in cerebellar 
mitochondria of PD Braak 5-6 females. Twelve oxylipin species and arachidonic acid are significantly reduced in the cerebellar mitochondria 
of females with PD Braak 5-6 when compared with controls. All samples were age matched. Braak 5-6 female n=5; control female n=5. (B) 
Two inflammatory cytokines are significantly lower in cerebellar mitochondria of PD Braak 5-6 females. ICAM-1 and TIMP-2 were significantly 
reduced in cerebellar mitochondria of PD Braak 5-6 females compared with female controls. Braak 5-6 female n=9; control female n=8. Plots 
display mean levels ± SEM. Red/blue titles represent pro- /anti-inflammatory, respectively. Refer to Supplementary Tables 3 and 5 for p 
values of oxylipins and inflammatory cytokines, respectively (Mann-Whitney U-test). (C) There is more variation in oxylipin content from 
cerebellar mitochondria of the female control group than the PD Braak 5-6 group. The female control group had significantly greater variance 
in eleven oxylipin quantities than PD Braak 5-6 females. PD Braak 5-6 female n=5; control female n=5. Box plots display interleaved high and 
low. The horizontal line represents the mean. Refer to Supplementary Table 4 for f values.  
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Arachidonic acid levels vary in PD cerebellar 
mitochondria 
 
AA is metabolized through well characterized pathways 
to generate a range of oxylipin species [18]. In control 
males we see quite similar and consistent levels of AA 
across the samples that were analysed (Figure 3C). 
However, there is significantly more variation in AA 
levels in both the PD Braak 3-4 samples (p=0.0072) and 
the PD Braak 5-6 samples (p=0.0209) when compared 
with controls (for f -test values see Supplementary 
Table 4). 
 
Mean levels and variation of levels of cytokines are 
increased in male PD Braak 5-6 cerebellar 
mitochondria 
 
Pro-inflammatory cytokines Eotaxin-1, I-309, IL-1β, 
IL-12p40, MIG, TNF RII, and anti-inflammatory IL-1ra 
and IL-12p70 were each found at significantly higher 
mean levels in the male PD Braak cerebellar 
mitochondria samples than in matched controls (Figure 
4A: for p values see Supplementary Table 5). The 
variation across the PD Braak 5-6 group was also much 
greater than across the control group (Figure 4B and for 
f-test values see Supplementary Table 6). Pro-
inflammatory cytokines BLC, Eotaxin, GM-CSF, I-309, 
IL-2, IL-6, IL-7, IL-12p40, IL-15, MIP-1d, PDGFB, 
RANTES, TNF RI, and anti-inflammatory cytokines IL-
5, IL-10, IL-12p70, MCSF and TNF RII each had 
significantly greater variance in levels across the PD 
Braak 5-6 group compared with controls. 
 
DISCUSSION 
 
Though much has been determined about PD associated 
changes in the cerebellum using imaging techniques, 
specific molecular and pathological evidence is scant [1, 
36, 37]. Epigenetic changes in PD cerebellum have been 
investigated and give good reason to anticipate that 
regulatory pathways are changed during the disease 
course [6, 38]. Mitochondrial dysfunction is a key 
feature of PD. Our molecular analyses of mitochondrial 
fractions now show quite clearly that there are disease 
associated changes of inflammation pathways in PD 
cerebellum. 
 
Inflammatory processes in the context of PD have 
suddenly been placed in the spotlight with the discovery 
that mitophagy proteins PINK1 and Parkin (both are 
implicated in familial PD) are important for regulating 
innate immunity and inflammation as shown in rodent 
models [11, 39]. We are the first to quantify molecular 
changes consistent with dysregulation of inflammatory 
processes in mitochondrial fractions of post-mortem 
human cerebellum. The role of neuroinflammation in 
PD is going to take some unravelling, but our data 
establish the cerebellum as a region that is affected in 
the disease process. Neuroinflammation has been shown 
to commence early in PD, peaking in moderately 
affected individuals, this fits with our data on PD Braak 
3-4 subjects [40]. CSF and plasma DHA derived 
resolvin D1 (RvD1) are reduced in patients with early-
onset PD [41], suggesting that inflammation resolution 
processes could be dysfunctional. We find the picture is 
complex, as should be expected, with both anti- and 
pro-inflammatory processes activated simultaneously to 
tune a potentially compensatory response to disease.  
 
Sex differences in PD are recognized but have not been 
investigated thoroughly, particularly from a biochemical 
aspect [42–44]. Differences in development of the 
immune system and lifelong neuro-epigenetic 
differences in brain inflammatory profiles have been 
explored in rodents but the extent to which these 
findings translate to the human brain is not clear [45]. 
Specifically interesting in PD is the role of the testis-
determining factor gene SRY [46]. In mouse, the SRY 
gene promotes catecholamine production by 
dopaminergic neurons of the substantia nigra [47], and 
rat models with repressed SRY expression show 
protection from experimentally induced PD [48]. A 
recent analysis shows an elevated prevalence of PD in 
females with the LRRK2 G2019S mutation [49]. Sexual 
dimorphism has been observed in the inflammatory 
response to traumatic brain injury in rodents [50, 51], 
and there is some limited information on sex differences 
in eicosanoid biology [52]. It is suggested that females 
can mount a more acute and efficient immune response, 
and subsequently resolve it more effectively than males 
[53–55]. The heterogeneity we see in the levels of 
inflammatory molecules in female controls could be 
responsible for the delay in onset and other phenotypic 
sex differences in PD. We found RANTES, a 
chemokine that induces infiltration into T-cells, to be 
significantly increased in female control cerebellar 
mitochondria compared with males. Decreasing 
RANTES in the substantia nigra has been shown to 
prevent loss of dopaminergic neurons in mouse models 
of PD [56]. In human PD, post-mortem substantia nigra 
contains more RANTES confirming association with 
disease but not necessarily with cell death in this region. 
From our study it is difficult to tell whether control 
females with low levels of the markers that are 
significantly more varied in the female control group, 
are at a higher risk for PD in the future. We show that 
sex differences are important to define in all studies of 
PD. Sex specific datasets can give clues about disease 
mechanism and pave the way to personalized medical 
approaches. Measurement of many markers of 
inflammatory processes in our study show that the 
control female groups have a greater range of these 
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Figure 3. Comparison of PD cerebellar mitochondria with different Braak classification. (A) Free fatty acid concentration is 
increased in cerebellar mitochondria of PD Braak stage 5-6 males. A significant increase in FFA levels was shown in cerebellar mitochondria of 
Braak stage 5-6 males compared to age-matched controls (p=0.0164). No significant differences were apparent between PD Braak stage 3-4 
and control. PD Braak 3-4 males (n=5), PD Braak 5-6 males (n=5), age-matched control males (n=10). Plots show mean values (nmol/µl) ± SEM 
(Kruskal-Wallis test with multiple comparisons). (B) Cerebellar levels of PTGS2 in PD Braak 5-6 mitochondrial fractions are lower compared 
with PD Braak 3-4 and controls. PTGS2 measured in enriched mitochondrial fractions were present in significantly lower quantities in the 
cerebellum of PD Braak 5-6 males compared to male controls (p=0.0307). No significant difference in PTGS2 levels were seen between PD 
Braak 3-4 and age-matched control. Mitochondrial PTGS2 levels, normalized to β-actin, were determined by Western blotting using 
mitochondrial and cytosolic fractions extracted from cerebellar tissue from age-matched male control (n=10) and PD Braak 3-4 (n=5) and 5-6 
(n=4). Columns show the mean ±SEM (Kruskal-Wallis test with multiple comparisons). (C) Oxylipin concentrations in cerebellar mitochondria. 
LTB-4 is significantly decreased in PD Braak 5-6 males (n=5) compared to PD Braak 3-4 males (n=5); p=0.0139 (Kruskal-Wallis test with 
multiple comparisons). No significant differences were apparent between PD male groups and age-matched male controls (n=5). Red /blue 
titles represent pro- /anti-inflammatory, respectively. No significant changes were found between control males and PD Braak 5-6 males. 
Plots display mean concentration (pmol/g) ±SEM. Refer to Supplementary Table 5 for all p values (Kruskal-Wallis test with multiple 
comparisons). (D) Arachidonic acid levels in PD. Cerebellar mitochondrial arachidonic acid levels are similar in control males but significant 
variation is seen in PD Braak 3-4 and 5-6 males. Refer to Supplementary Table 4 for f values. All samples were age matched. PD Braak 3-4 
male n=5; PD Braak 5-6 male n=5; control male n=5. 
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molecules with significantly higher mean levels. The 
greater range seen in females is interesting and needs to 
be explored further. It may be that younger females 
have generally high levels and the lower values seen in 
these age groups reflect a reduction associated with 
increased age. All this leads to the suggestion that 
neuroinflammatory responses measured as increases in 
oxylipins and cytokines, may be a protective state or 
acute response which changes or becomes exhausted in 
chronic disease states [57, 58]. This is potentially 
supported by the data shown for trends in the male 
groups where we were able to measure levels of 
oxylipins in control, PD Braak3-4 and PD Braak 5-6 
cerebellar mitochondria. Though significance was only 
reached in the case of LTB-4 there was a trend towards 
an increase in levels of inflammatory molecules at the 
earlier disease stage (PD Braak 3-4), which was abated 
in the more severely affected PD Braak 5-6 group. The 
 
 
 
Figure 4. Cytokine levels in PD Braak 5-6 male cerebellar mitochondria (A) Mean levels of cytokines are higher in cerebellar mitochondria of 
PD Braak 5-6 males. Eight inflammatory cytokines were increased in cerebellar mitochondria of PD Braak 5-6 males compared with control 
males. PD Braak 5-6 male n=10; control male n=9. Red or blue titles represent pro- /anti-inflammatory, respectively. Plots display mean 
concentration (pg/ml) ± SEM (Mann-Whitney test), see Supplementary Table 5 for p values (Mann-Whitney U test). (B) PD Braak 5-6 males 
show different variance in cerebellar mitochondrial cytokines levels than was seen in the control male group. All seventeen measured 
inflammatory cytokines with significant differences in variance are more dispersed from the mean in PD Braak 5-6 males than control males. 
PD Braak 5-6 male n=10; PD Braak 5-6 female n=9; control male n=9; control female n=8. Box plots display interleaved high and low. The 
horizontal line represents the mean. Data shown are oxylipins (A+B) with significant variances (f-test). Refer to Supplementary Table 6 for f 
values. 
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reduced range, or flat level of the molecules being 
measured in PD Braak 5-6 males is striking. This is a stage 
of disease that is clearly advanced with massive cell losses 
in the substantia nigra, it may be that the inflammatory 
response has been exhausted in the earlier stages of the 
disease. LTB-4 has been implicated previously in PD 
studies [59], but due to the poor correlation of rodent 
model PD to human disease it is difficult to draw any real 
conclusions about its precise role in the process. 
 
Patterns of cytokine levels add further to the complexity of 
the picture of neuroinflammation in PD. Mean increases of 
both pro- and anti-inflammatory cytokines in cerebellar 
mitochondria could be used to define the male PD Braak 
5-6 group. The most significant of these increases were in 
the pro-inflammatory molecules I-309 and TNF RII, 
followed by IL-1β and anti-inflammatory IL-1ra. TNF-RII 
antagonists have been proposed to have a therapeutic 
effect upon PD disease pathways, suggesting that this 
increase may be initiated in the cerebellum to compensate 
disease process in the substantia nigra [60]. Similar 
proposals have been made with respect to the cytokine I-
309 [61]. There are a few studies on IL-1β and IL-1ra in 
the context of PD, supporting the idea of inflammatory 
responses in brain regions other than the substantia nigra. 
 
We have compiled a molecular profile of inflammation 
in PD cerebellar mitochondria. This study emphasizes 
that that there are interesting molecular changes in the 
cerebellum that correlate with PD. Our findings 
highlight the need to establish sex specific differences 
in disease at the molecular level when these are 
recognized in the clinical phenotype.  
 
MATERIALS AND MATHODS 
 
Human post-mortem cerebellar samples 
 
This study was performed with ethical approval from 
Parkinson’s UK Brain Bank and University of 
Nottingham SVMS Ethics committee (Reference# 2035 
170519). Please see Supplementary Table 1 for 
information on patients and controls used in this study. 
Cerebellar mitochondria were isolated from 24 control, 
and 34 PD post-mortem brains. PD cases were further 
classified into Braak stages 3-4 and 5-6 respectively. 
Braak staging was assigned at the Parkinson’s UK Brain 
Bank according to published classification [62]. 
Oxylipin and cytokine profiling experiments used 
different post-mortem brain sample sets precluding 
sample group specific conclusions. 
 
Mitochondrial isolation 
 
Enriched mitochondrial fractions were separated by 
differential centrifugation according to our previously 
published protocols [63]. Briefly, previously flash 
frozen cerebellar samples were placed in GentleMACS 
C tubes with mitochondria extraction buffer (50 mM 
Tris-HCl ph7.4, 100 mM KCl, 1.5 mM MgCl2, 1 mM 
EGTA, 50 mM HEPES and 100 mM sucrose; all 
sourced from Sigma-Aldrich, UK) and homogenized 
using a GentleMACS Dissociator (Miltenyi Biotec). 
The resulting homogenates were spun at 4°C in an 
Eppendorf Model 5417R Microcentrifuge (Fisher 
Scientific); first at 850 x g for 10 minutes, then the 
supernatant obtained was centrifuged separately at 1000 
x g for 10 minutes to yield a nuclear pellet and a final 
spin at 10000 x g for 30 minutes to produce the 
mitochondrial pellet; the remaining supernatant 
contained the cytosolic fraction. Fractions were stored 
at -80°C. 
 
Protein assay 
 
The protein concentrations of the samples were 
determined using the Bradford Assay - Sigma [64]. 
Bovine serum albumin (BSA- Fisher Scientific) 
standards of known protein concentration varying from 
0 to 2mg/ml were added to Bradford reagent in 
disposable cuvettes (Fisher Scientific) and the 
absorbance was measured spectrophotometrically at 595 
nm in a Thermo Scientific Spectrometer Helios Episilon 
(Fisher Scientific). The absorbance of the known 
protein standards was plotted using linear regression. 
The mitochondrial fractions were diluted 1 µl in 100 µl 
Tris Buffer and added to Bradford reagent before the 
absorbance was measured. The absorbance was plotted 
against the BSA standard curve to determine the 
estimated protein concentration (mg/ml).  
 
Western blot  
 
Western blotting for quality control of fractions was 
carried out as described previously [65]. Antibody 
dilutions: PTGS2 ab62331 (Abcam) 1:2000 dilution in 
5% (w/v) BSA in 1xTBS-T; β-actin ab8227 (Abcam) in 
5% (w/v) BSA in 1xTBS-T; Goat anti-Rabbit IgG 
(HRP) A16096 (Invitrogen) 1:1000 in 5% (w/v) BSA in 
1xTBS-T. Mitochondrial fractions were normalized to 
β-actin level. Blots were visualized using ChemiDoc 
MP Imaging System (Bio-Rad) and ECL Plus reagent 
(Pierce). Densitometry was carried out using ImageJ. 
Statistical analyses were carried out in GraphPad Prism. 
 
Free fatty acid quantitation  
 
Total fatty acid concentration was measured using a 
Free Fatty Acid Quantification Kit (AB65341, Abcam), 
according to manufacturer’s instructions. Fatty acid 
concentrations were quantified by fluorometric analysis 
(Varioskan LUX Multimode Microplate Reader).  
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Oxylipin quantitation 
 
LC-ESI--MS/MS was used for analysis of oxylipins  
(AA, LA, 12-HETE, TXB-2, PGE2, 5-HETE, 5-
HPETE, 12-HPETE, 9-HETE, 20-HETE, LTB-4, 9-
oxoODE, 9-HODE, 5,6-EET, 5,6-DHET, 8,9-DHET, 
11,12-DHET, 14,15-DHET, 8-HETE, 11-HETE, 15-
HETE, 16-HETE, 8,9-EET, 11,12-EET, 14,15-EET, 17-
HDoHE, 13-oxoODE, 13-HODE, 8,15-DiHETE) in 
mitochondrial fractions of human cerebellar tissue. A 
gradient LC method based on that described by Wong et 
al (14) using a modular Shimadzu Vp series HPLC was 
used to introduce the samples. Injection volume was 
20µl. The MS system used was a triple quadrupole ion-
trap 4000 QTRAP (Sciex, UK), equipped with Turbo 
Spray ionization interface. Standards were purchased 
from Cambridge Biosciences, Cambridge, UK. One 
batch of QC human plasma standard samples (from in-
house stock) was used to confirm the intra-day accuracy 
of the method. 
 
Endocannabinoids quantitation 
 
LC-ESI--MS/MS was used for analysis of 
endocannabinoids: arachidonyl ethanolamide 
(anandamide, AEA), 2-arachidonyl glycerol (2-AG), 
palmitoyl ethanolamide (PEA), oleoyl ethanolamide 
(OEA) in mitochondrial fractions of human cerebellar 
tissue. A uHPLC system, a modular Exion series LC 
(Sciex, Warrington, UK) was used to create a 10 min 
gradient and introduce the 5µl sample. The column 
(uPLC BEH C18 1.7µm (2.1x150mm, Waters, Elstree, 
UK) was held at 60°C [66]. The MS system used was a 
Qtrap 6500+ (Sciex, Warrington, UK) equipped with an 
electrospray ionization (ESI) interface. Standards were 
purchased from Cambridge Biosciences, Cambridge, 
UK. One batch of QC human plasma standard samples 
(from in-house stock) was used to confirm the intra-day 
accuracy of the method. 
 
Human inflammation antibody array 
 
Abcam human inflammation antibody array (ab197451) 
kit was used for the detection of 40 cytokines: BLC, 
eoxtaxin-1, eotaxin-2, G-CSF, GM-CSF, I-309, ICAM-
1, IFNγ, IL-1α, IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-
6sR, IL-7, IL-8, IL-10, IL-11, IL-12p40, IL-12p70, IL-
13, IL-15, IL-16, IL-17. MCP-1, MCSF, MIG, MIP-1α, 
MIP-1β, MIP-1δ, PDGF-BB, RANTES, TIMP-1, 
TIMP-2, TNFα, TNFβ, sTNF RI, sTNF RII (guide to 
abbreviations in Supplementary Table 2). Glass slides 
contained 16 identical antibody arrays, with a 16 well 
gasket for addition of separate samples to each array. 
Antibodies were spotted in quadruplicate in each array. 
Protocol was followed as per manufacturer’s 
instructions. Briefly, gasket wells were blocked for 30 
minutes in Sample Diluent, followed by addition of a 
standard cytokine cocktail or 100ug of sample, diluted 
in PBS. The cocktail of standard cytokines was diluted 
three-fold across eight dilutions and 100ul was added to 
each well for 60 minutes. Slides were washed in 
supplied wash buffer 7 times for 5 minutes each, with 
gentle agitation at room temperature. The detection 
antibody was reconstituted in 1.4ml sample diluent and 
80ul added to each well and incubated overnight at 4°C, 
with gentle agitation. Subsequently, another 7 washes 
were carried out, as described above. 80ul of Cy3 
equivalent dye-conjugated streptavidin was added to 
each well. At this step, the slide was covered in 
aluminium foil to avoid exposure to light and incubated 
at room temperature for 1 hour. A further 5 wash steps 
for 5 minutes each followed. A final 2 wash steps were 
carried out for 15 minutes each. Finally, slides were 
completely dried with 3 times 3-minute centrifugation 
steps at 1,000rpm. For signal visualization, slides were 
scanned at 532nm and data analysed using GenePix Pro 
Software (Axon GenePix). The median local 
background was subtracted from the median 
fluorescence of each spot and the corrected fluorescence 
was used to calculate the average fluorescence signal as 
well as the standard deviation.  
 
Statistical analysis 
 
Data from the various experiments were presented as 
mean average alongside calculated standard deviation 
and standard error mean. Mann-Whitney U and 
Kruskal-Wallis tests were performed on the datasets 
using GraphPad Prism version 6 for Windows 
(GraphPad Software, San Diego California USA). 
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SUPPLEMENTARY MATERIALS 
 
Supplementary Figures 
 
 
 
 
 
 
 
 
Supplementary Figure 1. A large variation of oxylipin concentration is seen in the control female group. Comparison of 
measured oxylipins in cerebellar mitochondria from PD males (Braak 3-4 and 5-6) and PD females (Braak 5-6) and age-matched controls. PD 
Braak 3-4 male n=5; PD Braak 5-6 male n=5; PD Braak 5-6 female n=5; control male n=5; control female n=5. Plots display mean quantities 
(pmol/g) ± SEM. For p and f values refer to Supplementary Tables 3 and 4. 
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Supplementary Figure 2. Graphical comparisons of all measured inflammatory cytokines from cerebellar mitochondria of 
males and females with Braak stage 5-6 Parkinson’s disease and age-matched controls. PD Braak 5-6 male n=10; PD Braak 5-6 
female n=9; control male n=9; control female n=8. Plots display mean concentration (pg/ml) ± SEM. For all p or f values refer to 
Supplementary Tables 5 or 6, respectively. 
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Supplementary Tables 
 
Supplementary Table 1. Human post-mortem samples information. 
ID Diagnosis Age (yr) Sex Disease duration (yr) α-syn Cause of death 
Post mortem 
delay (hr) 
75/02 Control 61 F N/A N/A Not reported N/A 
CO48 Control 68 M N/A N/A Metastatic colon cancer 10 
CO22 Control 69 F N/A N/A Lung cancer 33 
PDC008 Control 71 F N/A N/A Myocardial infarction 17 
PDC030 Control 77 M N/A N/A Conductive cardiac failure 17 
CO45 Control 77 M N/A N/A Multiple (old age) 22 
CO26 Control 78 F N/A N/A Myeloid leukaemia 33 
61/07 Control 81 M N/A N/A Not reported N/A 
PDC029 Control 82 M N/A N/A Metastatic liver/lung cancer 48 
PDC005 Control 58 M N/A N/A Not reported 9 
PDC022 Control 65 M N/A N/A Lung carcinoma 12 
PDC034 Control 90 M N/A N/A Respiratory failure 12 
PDC016 Control 93 F N/A N/A Bronchial pneumonia/old 22 
PDC026 Control 80 F N/A N/A Breast carcinoma 23 
PDC023 Control 78 F N/A N/A Not reported 23 
PDC008 Control 71 F N/A N/A Myocardial infarction 17 
PDC028 Control 84 F N/A N/A Pancreatic cancer 11 
PDC027 Control 79 M N/A N/A Cardiac arrest & pneumonia 21 
PDC092 Control 79 M N/A N/A Brainstem stroke, bronchopneumonia 25 
PDC014 Control 64 M N/A N/A Cardiac failure 18 
PDC078 Control 91 M N/A N/A Not reported 18 
PDC105 Control 95 M N/A N/A Pneumonia, cellulitis of leg 11 
PDC053 Control 89 F N/A N/A Not reported 22 
PDC040 Control 61 F N/A N/A Ovarian cancer 15 
PD081 Braak 3-4 73 M 9 6 Not reported 19 
PD036 Braak 3-4 76 M 10 3 Not reported 10 
PD041 Braak 3-4 77 M 10 6 Not reported 6 
PD007 Braak 3-4 78 M 10 3 Pneumonia 22 
PD067 Braak 3-4 83 M 9 6 Not reported 10 
PD051 Braak 3-4 80 M 5 5 Not reported 7 
PD067 Braak 3-4 83 M 9 N/A Not reported 10 
PD081 Braak 3-4 73 M 9 N/A Not reported 19 
PD084 Braak 3-4 78 M 9 5 Ischaemic bowel and atrial fibrillation 3 
PD074 Braak 3-4 85 M 5 5 bronchopneumonia 7 
002/08 Braak 5-6 69 M 1 Not available Not reported N/A 
PD131 Braak 5-6 76 F 11 6 Not reported 22 
044/07 Braak 5-6 78 M 6 Not available Not reported N/A 
PD014 Braak 5-6 79 M 12 3 Parkinson’s 21 
PD063 Braak 5-6 80 F 13 4 Old age and PD 10 
PD028 Braak 5-6 82 M 18 6 Not reported 14 
PD050 Braak 5-6 82 F 14 6 Chest infection & CVA 18 
PD099 Braak 5-6 82 M 11 6 Pneumonia 10 
PD016 Braak 5-6 85 F 18 6 Bronchopneumonia/PD 14 
PD045 Braak 5-6 80 M 19 6 Not reported 16 
PD028 Braak 5-6 82 M 18 6 Not reported 14 
PD079 Braak 5-6 78 F 19 6 Chest infection & CVA 22 
PD016 Braak 5-6 85 F 18 6 Bronchopneumonia/PD 14 
PD125 Braak 5-6 74 M 25 6 Bronchopneumonia/PD 20 
PD117 Braak 5-6 77 F 31 5 Not reported 6 
PD021 Braak 5-6 76 M 27 6 Not reported 17 
PD020 Braak 5-6 75 M 34 6 Not reported 2 
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PD117 Braak 5-6 77 F 31 5 Not reported 6 
PD017 Braak 5-6 75 M 18 6 Not reported 22 
PD180 Braak 5-6 85 F 15 6 Chest infection & PD   15 
PD093 Braak 5-6 81 F 14 6 Not reported 22 
PD203 Braak 5-6 84 F 18 6 PD 19 
PD413 Braak 5-6 72 F 21 6 Pneumonia 14 
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Supplementary Table 2. Abbreviations and corresponding full names of all oxylipins, inflammatory cytokines and 
endocannabinoids used in this work. 
Abbreviation   
Oxlipins   
AA Arachidonic acid 
LA Linoleic acid 
12-HETE 12-hydroxyeicosatetraenoic acid 
TXB-2 Thromboxane B2 
PGE2 Prostaglandin E2 
5-HETE 5-Hydroxyeicosatetraenoic acid 
5-HPETE Arachidonic acid 5-hydroperoxide 
12-HPETE Arachidonic acid 12-hydroperoxide 
9-HETE 9-Hydroxyeicosatetraenoic acid 
20-HETE 20-Hydroxyeicosatetraenoic acid 
LTB-4 Leukotriene B4 
9-oxoODE 9-oxo-10E,12Z-octadecadienoic acid 
9-HODE 9S-Hydroxy-10E,12Z-octadecadienoic acid 
5,6-EET 5,6-epoxyeicosatrienoic acid 
5,6-DHET 5,6-dihydroxyeicosatrienoic acid 
8,9-DHET 8,9-dihydroxyeicosatrienoic acid 
11,12-DHET 11,12-dihydroxyeicosatrienoic acid 
14,15-DHET 14,15-dihydroxyeicosatrienoic acid 
8-HETE 8-Hydroxyeicosatetraenoic acid 
11-HETE 11-Hydroxyeicosatetraenoic acid 
15-HETE 15-Hydroxyeicosatetraenoic acid 
16-HETE 16-Hydroxyeicosatetraenoic acid 
8,9-EET 8,9-epoxyeicosatrienoic acid 
11,12-EET 11,12-epoxyeicosatrienoic acid 
14,15-EET 14,15-epoxyeicosatrienoic acid 
17-HDoHE 17-Hydroxydocosahexaenoic acid 
13-oxoODE 13-Oxo-9,11-octadecadienoic acid 
13-HODE 13-hydroxy-9Z,11E-octadecadienoic acid 
8,15-DiHETE 8,15-Leukotriene B4 
Endocannabinoids   
2-AG 2-Arachidonoylglycerol 
AEA Anandamide 
OEA Oleylethanolamide 
PEA Palmitoylethanolamide 
    
Inflammatory cytokines   
BLC B Cell-Attracting Chemokine 1 
Eotaxin C-C Motif Chemokine Ligand 11 (CCL11) 
Eotaxin-2 C-C Motif Chemokine Ligand 24 (CCL24) 
G-CSF Granulocyte Colony-Stimulating Factor 
GM-CSF Granulocyte-Macrophage Colony-Stimulating Factor 
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I-309 C-C Motif Chemokine Ligand 1 (CCL1) 
ICAM-1 Intercellular Adhesion Molecule 1 
IFNγ Interferon Gamma 
IL-1α Interleukin 1 Alpha 
IL-1β Interleukin 1 Beta 
IL-2 Interleukin 2 
IL-6 Interleukin 6 
IL-6sR Interleukin 6 soluble receptor 
IL-7 Interleukin 7 
IL-8 Interleukin 8 
IL-12p40 IL-12 Subunit P40 
IL-12p70 IL-12 Subunit P70 
IL-15 Interleukin 15 
IL-16 Interleukin 16 
IL-17 Interleukin 17 
MCP-1 Monocyte Chemotactic And Activating Factor 
MIG Monokine Induced By Interferon-Gamma 
MIP-1α Macrophage Inflammatory Protein 1-Alpha 
MIP-1β Macrophage Inflammatory Protein 1-Beta 
MIP-1δ Macrophage Inflammatory Protein 1-Delta 
PDGF-BB Platelet Derived Growth Factor Subunit B 
RANTES Regulated Upon Activation, Normally T-Expressed, And Secreted 
TNFα Tumor Necrosis Factor-Alpha 
TNFβ Tumor Necrosis Factor-Beta 
TNF RI Tumor Necrosis Factor Receptor 1 
TNF RII Tumor Necrosis Factor Receptor 2 
IL-1ra Interleukin 1 Receptor Antagonist 
IL-4 Interleukin 4 
IL-5 Interleukin 5 
IL-10 Interleukin 10 
IL-11 Interleukin 11 
IL-13 Interleukin 13 
MCSF Macrophage Colony-Stimulating Factor 1 
TIMP-1 Tissue Inhibitor Of Metalloproteinases 1 
TIMP-2 Tissue Inhibitor Of Metalloproteinases 2 
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Supplementary Table 3. Mean comparisons of all 29 measured oxylipins from cerebellar mitochondria. 
Oxylipin 
Control 
males vs 
control 
females 
Braak 5-6 
males vs 
Braak 5-6 
females 
Braak 5-6 
males vs 
control males 
Braak 3-4 
males vs 
control males 
Braak 3-4 
males vs 
Braak 5-6 
males 
Braak 3-4 
males vs 
control 
females 
Braak 5-6 
females vs 
control 
females 
                
AA 0.4206 0.1429 >0.9999 >0.9999 0.688 0.6905 0.0317* 
LA 0.4206 0.1984 >0.9999 >0.9999 >0.9999 0.6905 0.0556 
12-HETE 0.0079** 0.5159 0.5373 0.1209 >0.9999 0.2222 0.0317* 
TXB-2 0.0556 0.8571 >0.9999 0.1687 0.0589 0.5476 0.0317* 
PGE2 0.2222 0.6032 >0.9999 0.198 0.7737 >0.9999 0.2778 
5-HETE 0.2222 0.3968 >0.9999 0.1687 0.6093 0.6905 0.0476* 
5-HPETE 0.0952 0.381 >0.9999 >0.9999 0.8665 0.5476 0.0317* 
12-HPETE 0.3095 0.6508 0.6905 0.3095 0.5476 0.5476 0.0476* 
9-HETE 0.2222 0.8016 >0.9999 0.1431 0.3116 0.5476 0.0873 
20-HETE 0.2222 0.5238 >0.9999 0.4127 0.6093 0.8413 0.0873 
LTB-4 0.4206 0.7857 >0.9999 0.1204 0.0139* 0.6905 0.2063 
9-oxoODE 0.3095 0.1905 >0.9999 >0.9999 >0.9999 0.4206 0.0476* 
9-HODE 0.2222 0.1905 >0.9999 0.3339 0.0774 0.6905 0.0476* 
5,6-EET 0.1508 0.381 >0.9999 0.4719 >0.9999 0.8413 0.0317* 
5,6-DHET 0.3095 0.5238 0.6081 0.1311 >0.9999 0.5476 0.381 
8,9-DHET 0.2222 0.5397 >0.9999 0.5373 >0.9999 0.3095 0.2063 
11,12-DHET 0.2222 0.3968 >0.9999 0.3116 0.7737 0.5476 0.1349 
14,15-DHET 0.3095 0.5159 >0.9999 0.2691 0.6093 0.4206 0.1984 
8-HETE 0.2222 0.381 >0.9999 0.0589 0.2691 0.6905 0.0873 
11-HETE 0.2222 0.5 >0.9999 0.1687 0.1017 0.8413 0.1349 
15-HETE 0.1508 0.5238 >0.9999 0.3116 0.3594 0.6905 0.0873 
16-HETE 0.3095 0.3968 >0.9999 0.2313 0.198 0.8413 0.0476* 
8,9-EET 0.2222 0.2778 >0.9999 0.071 0.3594 0.6905 0.0873 
11,12-EET 0.2222 0.5159 >0.9999 0.198 0.0851 0.6905 0.1984 
14,15-EET 0.1508 0.5238 >0.9999 0.4127 0.6093 0.6905 0.0873 
17-HDoHE 0.2222 0.381 >0.9999 >0.9999 >0.9999 0.6905 0.0476* 
13-oxoODE 0.2222 0.2857 >0.9999 >0.9999 >0.9999 0.3095 0.0476* 
13-HODE 0.2222 0.1905 >0.9999 0.2691 0.1017 0.5476 0.0476* 
8,15-DiHETE >0.9999 0.5238 >0.9999 0.5338 >0.9999 0.0952 0.8968 
PD Braak 3-4 male n=5; PD Braak 5-6 male n=5; PD Braak 5-6 female n=5; control male n=5; control female n=5. Statistical analyses 
were carried out using GraphPad Prism (Kruskal-Wallis test with multiple comparisons or Mann-Whitney U-test where appropriate). 
Red and blue font oxylipins represent pro- and anti-inflammatory, respectively. Bright yellow shaded numbers refer to significance 
(*p<0.05; **p<0.01). 
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Supplementary Table 4. Group variance analyses of all 29 measured oxylipins from cerebellar mitochondria. 
Oxylipin 
Control 
males vs 
control 
females 
Braak 5-6 
males vs 
Braak 5-6 
females 
Braak 5-6 
males vs 
control males 
Braak 3-4 
males vs 
control males 
Braak 3-4 
males vs 
Braak 5-6 
males 
Braak 3-4 
males vs 
control 
females 
Braak 5-6 
females vs 
control 
females 
AA 0.001** 0.9319 0.0209* 0.0072** 0.5974 0.3514 0.1354 
LA 0.0048** 0.3855 0.4618 0.9381 0.4176 0.0041** 0.0036** 
12-HETE 0.4458 0.9151 0.2903 0.453 0.7467 0.9901 0.8379 
TXB-2 0.5039 0.903 0.6142 0.2706 0.5359 0.0895 0.2078 
PGE2 0.0517 0.125 0.4369 0.349 0.8676 0.2616 0.0104* 
5-HETE 0.0402* 0.2352 0.2075 0.3246 0.7657 0.2306 0.0468* 
5-HPETE 0.1729 0.0686 0.538 0.6102 0.2696 0.0715 0.0149* 
12-HPETE 0.3939 0.0208* 0.9326 0.2237 0.1959 0.0503 0.0043** 
9-HETE 0.0878 0.8281 0.948 0.3884 0.3553 0.3558 0.1145 
20-HETE 0.0641 0.9358 0.5881 0.2454 0.5188 0.4326 0.1447 
LTB-4 0.0567 0.454 0.7851 0.3996 0.5632 0.0108* 0.1338 
9-oxoODE 0.0173* 0.2025 0.8634 0.2913 0.3717 0.0019** 0.0008*** 
9-HODE 0.0272* 0.2072 0.7879 0.6756 0.8803 0.0119* 0.0011** 
5,6-EET 0.1154 0.0308* 0.6494 0.5482 0.2996 0.0385* 0.0027** 
5,6-DHET 0.1545 0.5922 0.4865 0.1216 0.3628 0.8868 0.8066 
8,9-DHET 0.1304 0.1762 0.7949 0.6324 0.4639 0.28 0.6597 
11,12-DHET 0.3047 0.158 0.8692 0.7037 0.5873 0.5078 0.0169 
14,15-DHET 0.137 0.9187 0.8623 0.669 0.5498 0.2709 0.1214 
8-HETE 0.0431* 0.8093 0.516 0.4253 0.8786 0.1791 0.2063 
11-HETE 0.0707 0.8643 0.535 0.5844 0.9402 0.1819 0.2665 
15-HETE 0.0759 0.8024 0.6538 0.5574 0.8881 0.2066 0.108 
16-HETE 0.268 0.4558 0.9429 0.8615 0.9181 0.2051 0.0674 
8,9-EET 0.0408* 0.8163 0.5151 0.3884 0.8263 0.1907 0.1947 
11,12-EET 0.0946 0.7192 0.7711 0.5743 0.7844 0.2406 0.274 
14,15-EET 0.0859 0.7794 0.675 0.5518 0.8582 0.2331 0.1098 
17-HDoHE 0.0951 0.1531 0.9555 0.7221 0.764 0.174 0.006** 
13-oxoODE 0.0085** 0.2321 0.7652 0.4311 0.2845 0.0016** 0.0012** 
13-HODE 0.0138* 0.1104 0.7363 0.3799 0.5811 0.0022** 0.0002*** 
8,15-DiHETE 0.5978 0.1323 0.0999 0.5292 0.2795 0.9173 0.7143 
PD Braak 3-4 male n=5; PD Braak 5-6 male n=5; PD Braak 5-6 female n=5; control male n=5; control female n=5. Statistical analyses 
were carried out using GraphPad Prism (f-test). Red and blue font oxylipins represent pro- and anti-inflammatory, respectively. 
Bright yellow shaded numbers refer to significance (*p<0.05; **p<0.01; ***p<0.001). 
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Supplementary Table 5. Statistical comparisons of all 40 measured inflammatory cytokines from cerebellar 
mitochondria. 
Inflammatory 
Cytokine 
Control males vs 
control females 
Braak 5-6 males vs 
Braak 5-6 females 
Braak 5-6 males vs 
control males 
Braak 5-6 females vs 
control females 
          
BLC 0.4807 0.1564 0.1823 0.5414 
Eotaxin 0.6058 0.4363 0.04* 0.0745 
Eotaxin-2 0.8884 0.077 0.0503 0.3704 
G-CSF 0.8884 0.3562 0.3154 >0.9999 
GM-CSF 0.0418* 0.4002 0.6607 >0.9999 
I-309 0.0745 0.5457 0.0005*** 0.4234 
ICAM-1 0.4234 >0.9999 0.0789 0.0274* 
IFNγ 0.8148 0.447 0.3562 0.6058 
IL-1α 0.9626 0.447 0.2428 0.743 
IL-1β 0.536 0.0545 0.0057** 0.3357 
IL-2 0.3213 0.447 0.7197 0.1388 
IL-6 0.4807 0.6607 0.549 0.5414 
IL-6sR 0.743 0.3562 0.6038 0.5414 
IL-7 0.3213 0.9048 0.9682 0.6058 
IL-8 0.743 0.9048 0.549 0.3213 
IL-12p40 0.8148 0.4894 0.0188* 0.1672 
IL-15 0.2766 0.9048 0.8421 0.3213 
IL-16 0.5414 0.8421 0.4967 0.6058 
IL-17 0.2359 0.8421 0.9048 0.6058 
MCP-1 0.8148 0.4002 0.1333 0.4807 
MIG 0.4807 0.2581 0.0188* 0.8148 
MIP-1α 0.1388 0.3154 0.3154 >0.9999 
MIP-1β 0.0927 >0.9999 0.0653 0.8148 
MIP-1δ 0.1812 0.4967 0.1728 0.2721 
PDGF-BB 0.1139 0.6038 0.3154 0.2359 
RANTES 0.007** 0.9682 0.1011 0.6058 
TNFα 0.9626 0.6607 0.9048 0.5414 
TNFβ 0.9626 0.3154 0.0789 0.6058 
TNF RI 0.9626 0.4967 0.1564 0.3704 
TNF RII 0.3213 0.2224 0.0012** 0.9626 
IL-1ra 0.6058 0.0535 0.0057** 0.8884 
IL-4 0.5414 0.9682 0.1823 0.8148 
IL-5 0.2359 0.4967 0.1823 0.673 
IL-10 0.4234 0.7802 0.6607 0.6058 
IL-11 0.1672 0.9048 0.7802 0.1996 
IL-12p70 0.743 >0.9999 0.0101* 0.3213 
IL-13 0.673 0.9682 0.6607 0.8148 
MCSF 0.743 0.4967 0.0653 0.1996 
TIMP-1 0.9182 0.4967 0.6607 0.9182 
TIMP-2 0.3704 0.7802 0.2428 0.036* 
PD Braak 5-6 male n=10; PD Braak 5-6 female n=9; control male n=9; control female n=8. Statistical analyses were carried out using 
GraphPad Prism (Mann-Whitney U-test). Red and blue font represent pro- and anti-inflammatory, respectively. Bright yellow 
shaded numbers refer to significance (*p<0.05; **p<0.01; ***p<0.001). 
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Supplementary Table 6. Statistical group variance analyses of all 40 measured inflammatory cytokines from 
cerebellar mitochondria. 
Inflammatory 
Cytokine 
Control males vs 
control females 
Braak 5-6 males vs 
Braak 5-6 females 
Braak 5-6 males vs 
control males 
Braak 5-6 females vs 
control females 
          
BLC 0.489 0.2784 0.0024** 0.1595 
Eotaxin 0.4921 0.4269 0.0017** 0.0723 
Eotaxin-2 0.0547 0.4614 0.0586 0.429 
G-CSF 0.0785 0.5697 0.269 0.1925 
GM-CSF 0.1593 0.2312 0.0004*** 0.2614 
I-309 0.114 0.7636 0.0054** 0.1258 
ICAM-1 0.6282 0.4518 0.0546 0.1108 
IFNγ 0.0864 0.7262 0.057 0.8382 
IL-1α 0.9418 0.1935 0.8813 0.321 
IL-1β 0.0221* 0.8982 0.4273 0.0042** 
IL-2 0.0155* 0.7287 0.0202* 0.5979 
IL-6 0.0001*** 0.7721 0.0065** 0.0755 
IL-6sR 0.0002*** 0.5675 0.2664 0.0145* 
IL-7 0.1184 0.8129 0.0419* 0.5199 
IL-8 0.0117* 0.6105 0.2609 0.2745 
IL-12p40 <0.0001**** 0.129 0.0013** 0.9745 
IL-15 0.0007*** 0.728 0.0263* 0.2327 
IL-16 0.0166* 0.1326 0.0653 0.4724 
IL-17 0.0279* 0.3974 0.5947 0.0138* 
MCP-1 0.0028** 0.1306 0.3733 0.3504 
MIG <0.0001**** 0.1617 0.0902 0.0155* 
MIP-1α 0.0575 0.0419* 0.7264 0.7378 
MIP-1β 0.0044** 0.0023** 0.5406 0.5712 
MIP-1δ 0.2335 0.732 0.0006*** 0.0005*** 
PDGF-BB 0.0203* 0.4083 0.0396* 0.6927 
RANTES 0.3007 0.1473 0.0046** 0.0026** 
TNFα 0.8404 0.0413* 0.7458 0.1598 
TNFβ 0.0155* 0.2411 0.3658 0.569 
TNF RI <0.0001**** 0.1133 <0.0001**** 0.1464 
TNF RII 0.0079** 0.0696 0.0123* 0.0479* 
IL-1ra 0.9013 0.998 0.362 0.3329 
IL-4 0.0349* 0.0005*** 0.0917 0.8174 
IL-5 0.1335 0.7278 0.0301* 0.755 
IL-10 <0.0001**** 0.6593 0.0095** 0.0097** 
IL-11 0.5622 0.7733 0.1148 0.024* 
IL-12p70 <0.0001**** 0.0408* 0.0004*** 0.337 
IL-13 0.0072** 0.5229 0.1929 0.3199 
MCSF 0.0052** 0.0439* 0.0367* 0.3129 
TIMP-1 0.793 0.0265* 0.7116 0.0087** 
TIMP-2 0.0139* 0.7664 0.6342 0.0022** 
PD Braak 5-6 male n=10; PD Braak 5-6 female n=9; control male n=9; control female n=8. Statistical analyses were carried out using 
GraphPad Prism (f-test). Red and blue font represent pro- and anti-inflammatory cytokines, respectively. Bright yellow shaded 
numbers refer to significance (*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001). 
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Supplementary Table 7. Statistical comparisons of endocannabinoids were carried out using GraphPad Prism 
(Kruskal-Wallis and f tests). 
Endocannabinoid 
Control males 
vs control 
females 
Braak 5-6 
males vs Braak 
5-6 females 
Braak 5-6  
females vs control 
females 
Braak 5-6  
males vs 
control males 
p-values     
2-AG >0.9999 >0.9999 >0.9999 >0.9999 
AEA >0.9999 >0.9999 >0.9999 >0.9999 
OEA >0.9999 >0.9999 0.9232 >0.9999 
PEA >0.9999 >0.9999 >0.9999 >0.9999 
f-values     
2-AG 0.1801 0.0441* 0.0336* 0.2331 
AEA 0.0829 0.9996 0.0164* 0.5157 
OEA 0.733 0.8458 0.6317 0.9572 
PEA 0.7027 0.0814 0.0397* 0.9634 
Bright yellow shaded numbers refer to significance (*p<0.05). Braak 5-6 male n=8; Braak 5-6 female n=9; control male n=8; control 
female n=6. All samples were age matched. 
